Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRB 796 BS in Moderate to Severe Crohn's Disease
NCT02209792Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2001
- Primary completion
- Jan 2004
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of doramapimod in Crohn's disease, sponsored by Boehringer Ingelheim. Started Oct 2001; status: terminated.
02
Drugs
doramapimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02209792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209792.